Open an account

Sutro Biopharma

STRO · NASDAQ

$11.54+$0.285 (+2.53%)TodayMarket closed ·
Prev close $11.25

About STRO

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 137 full-time employees. The company went IPO on 2018-09-27. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Employees
137
Headquarters
South San Francisco, California
Listed
Sep 27, 2018
Sector
Health Care
Industry
Biotechnology
Website
sutrobio.com

STRO key statistics

Market cap
186.62M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
297.22K
Volume
273.87K
Open price
$11.25
High today
$11.70
Low today
$11.11
52 Week high
$43.85
52 Week low
$7.15

Sutro Biopharma (STRO) at a glance

As of Oct 20, 2026, Sutro Biopharma (STRO) shares are priced at $11.54, giving the company a market cap of 186.62M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.11 and $11.70. The current price is 3.9% above the day's low and 1.4% below its high.

Volume so far is 273.87K shares, in line with the average of 297.22K shares a day.

Over the past year Sutro Biopharma has ranged from $7.15 to $43.85, and now sits 12% of the way up that range.

Sutro Biopharma met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$2.33 per share against an estimate of -$2.24.

The average analyst price target is $48.18, 317.5% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 15 analystsAvg $48.18
Low
$10.10
Now
$11.54
High
$64.05

STRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 36.9% on average.

  1. Q3 FY24: reported -$5.90 per share against an estimate of -$7.49
  2. Q4 FY24: reported -$8.90 per share against an estimate of -$8.48
  3. Q1 FY25: reported -$9.10 per share against an estimate of -$7.22
  4. Q2 FY25: reported -$1.40 per share against an estimate of -$4.10
  5. Q3 FY25: reported -$6.70 per share against an estimate of -$4.23
  6. Q4 FY25: reported -$5.29 per share against an estimate of -$4.43
  7. Q1 FY26: reported -$2.94 per share against an estimate of -$3.85
  8. Q2 FY26: reported -$2.33 per share against an estimate of -$2.24

STRO news

  • Vandana Singh

    Why is Sutro Biopharma Stock Falling On Wednesday?

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Gold Gains 1%; Performance Food Group Shares Fall After Q4 Results

  • Press releaseGlobe Newswire

    Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

  • Avi Kapoor

    XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releasePRNewswire

    Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Similar companies

Companies in the same industry as Sutro Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.